Neuron-specific enolase has potential value as a biomarker for [

FDG PET/CT Mismatch PSMA PET/CT Prostate cancer mCRPC

Journal

EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946

Informations de publication

Date de publication:
24 May 2020
Historique:
received: 21 02 2020
accepted: 04 05 2020
entrez: 26 5 2020
pubmed: 26 5 2020
medline: 26 5 2020
Statut: epublish

Résumé

PSMA-targeted radioligand therapy (PSMA-RLT) yielded impressive results in the metastasized castration-resistant prostate carcinoma (mCRPC) setting. High expression of PSMA is essential for successful PSMA-RLT. However, some patients develop [ Retrospective study of N = 66 advanced mCRPC patients with dual [ In total, 41/66 (62%) patients revealed at least one [ We observed a significantly higher absolute serum concentration and a higher relative increase of NSE in advanced mCRPC patients with [

Sections du résumé

BACKGROUND BACKGROUND
PSMA-targeted radioligand therapy (PSMA-RLT) yielded impressive results in the metastasized castration-resistant prostate carcinoma (mCRPC) setting. High expression of PSMA is essential for successful PSMA-RLT. However, some patients develop [
METHODS METHODS
Retrospective study of N = 66 advanced mCRPC patients with dual [
RESULTS RESULTS
In total, 41/66 (62%) patients revealed at least one [
CONCLUSION CONCLUSIONS
We observed a significantly higher absolute serum concentration and a higher relative increase of NSE in advanced mCRPC patients with [

Identifiants

pubmed: 32449086
doi: 10.1186/s13550-020-00640-2
pii: 10.1186/s13550-020-00640-2
pmc: PMC7246282
doi:

Types de publication

Journal Article

Langues

eng

Pagination

52

Références

Prostate. 2020 Jan;80(1):17-27
pubmed: 31579967
Nat Rev Cancer. 2015 Dec;15(12):701-11
pubmed: 26563462
Front Oncol. 2015 Apr 14;5:90
pubmed: 25927031
Front Oncol. 2014 Mar 25;4:60
pubmed: 24724054
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1054-1062
pubmed: 30697649
Ther Adv Med Oncol. 2019 Sep 20;11:1758835919876828
pubmed: 31565073
Eur Urol. 2019 Jun;75(6):920-926
pubmed: 30473431
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
Clin Genitourin Cancer. 2019 Feb;17(1):15-22
pubmed: 30425003
Target Oncol. 2017 Aug;12(4):401-412
pubmed: 28620691
J Clin Oncol. 2008 Jan 10;26(2):242-5
pubmed: 18182665
Endocr Relat Cancer. 2018 Oct 1;26(2):131-146
pubmed: 30400059
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
Prostate. 2001 Jun 15;48(1):7-15
pubmed: 11391682
Int J Clin Pract. 2011 Nov;65(11):1180-92
pubmed: 21995694
Front Oncol. 2017 Jun 19;7:131
pubmed: 28674679
Mol Imaging. 2018 Jan-Dec;17:1536012118776068
pubmed: 29873291
Nuklearmedizin. 2007;46(6):291-301
pubmed: 18084685
Int J Biol Markers. 2018 Jan;33(1):10-21
pubmed: 28885659
World J Surg Oncol. 2008 Jun 19;6:64
pubmed: 18565231
Eur Urol. 2017 Apr;71(4):630-642
pubmed: 27591931
Oncol Rep. 2008 Dec;20(6):1561-7
pubmed: 19020742
Prostate. 2014 Aug;74(11):1153-9
pubmed: 24913988
Future Oncol. 2018 Oct;14(24):2543-2556
pubmed: 29925281
Clin Nucl Med. 2015 Feb;40(2):e163-6
pubmed: 25275415
Clin Nucl Med. 2018 Apr;43(4):248-249
pubmed: 29474196
Clin Nucl Med. 2018 Oct;43(10):728-734
pubmed: 30059428
Front Oncol. 2015 Mar 03;5:37
pubmed: 25785244
Prostate. 2002 May 1;51(2):117-25
pubmed: 11948966
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):81-91
pubmed: 27506431
Prostate Cancer Prostatic Dis. 2012 Sep;15(3):283-8
pubmed: 22349984
Clin Cancer Res. 2014 Jun 1;20(11):2846-50
pubmed: 24727321
EJNMMI Res. 2019 Aug 29;9(1):84
pubmed: 31468235
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024
pubmed: 28283702
Crit Rev Clin Lab Sci. 2001 Aug;38(4):263-355
pubmed: 11563810
Nature. 1978 Dec 21-28;276(5690):834-6
pubmed: 31568
J Nucl Med. 2016 Oct;57(Suppl 3):79S-89S
pubmed: 27694178
Prostate Cancer Prostatic Dis. 2020 Jan 13;:
pubmed: 31932660
Prostate. 2011 May;71(6):642-8
pubmed: 20945407
Eur Urol Oncol. 2019 Nov;2(6):670-676
pubmed: 31412006
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544
pubmed: 31440799
Adv Exp Med Biol. 2015;867:125-43
pubmed: 26530364
Clin Genitourin Cancer. 2017 Feb;15(1):e65-e68
pubmed: 27751686
J Nucl Med. 2017 Aug;58(8):1196-1200
pubmed: 28663195
J Natl Compr Canc Netw. 2014 May;12(5):719-26
pubmed: 24812138
Clin Nucl Med. 2017 May;42(5):410-413
pubmed: 28240661
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593

Auteurs

Florian Rosar (F)

Department of Nuclear Medicine, Saarland University-Medical Center, Kirrberger Str. 100, Geb. 50, 66421, Homburg, Germany. florian.rosar@uks.eu.

Kalle Ribbat (K)

Department of Nuclear Medicine, Saarland University-Medical Center, Kirrberger Str. 100, Geb. 50, 66421, Homburg, Germany.

Martin Ries (M)

Department of Nuclear Medicine, Saarland University-Medical Center, Kirrberger Str. 100, Geb. 50, 66421, Homburg, Germany.

Johannes Linxweiler (J)

Department of Urology, Saarland University-Medical Center, Homburg, Germany.

Mark Bartholomä (M)

Department of Nuclear Medicine, Saarland University-Medical Center, Kirrberger Str. 100, Geb. 50, 66421, Homburg, Germany.

Stephan Maus (S)

Department of Nuclear Medicine, Saarland University-Medical Center, Kirrberger Str. 100, Geb. 50, 66421, Homburg, Germany.

Mathias Schreckenberger (M)

Department of Nuclear Medicine, University of Mainz, Mainz, Germany.

Samer Ezziddin (S)

Department of Nuclear Medicine, Saarland University-Medical Center, Kirrberger Str. 100, Geb. 50, 66421, Homburg, Germany.

Fadi Khreish (F)

Department of Nuclear Medicine, Saarland University-Medical Center, Kirrberger Str. 100, Geb. 50, 66421, Homburg, Germany.

Classifications MeSH